<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938830</url>
  </required_header>
  <id_info>
    <org_study_id>1654-007</org_study_id>
    <secondary_id>2020-005996-11</secondary_id>
    <secondary_id>MK-1654-007</secondary_id>
    <nct_id>NCT04938830</nct_id>
  </id_info>
  <brief_title>MK-1654 in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and tolerability of MK-1654 compared to palivizumab as&#xD;
      assessed by the proportion of participants experiencing adverse events (AEs).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">April 27, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with solicited injection-site Adverse Events (AEs) in RSV Season 1</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Percentage of participants with solicited injection-site AEs in RSV Season 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with solicited daily body temperature with fever in RSV Season 1</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Percentage of participants with solicited daily body temperature with fever in RSV Season 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with solicited systemic AEs in RSV Season 1</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Percentage of participants with solicited systemic AEs in RSV Season 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with anaphylaxis/hypersensitivity AEs of special interest (AESI) in RSV Season 1</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Percentage of participants with anaphylaxis/hypersensitivity AESI in RSV Season 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with rash AESI in RSV Season 1</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Percentage of participants with rash AESI in RSV Season 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with non-serious AEs in RSV Season 1</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Percentage of participants with non-serious AEs in RSV Season 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>participants with serious AEs (SAEs) through the duration of participation in RSV Season 1</measure>
    <time_frame>Up to 365 days</time_frame>
    <description>Percentage of participants with serious AEs (SAEs) through the duration of participation in RSV Season 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants with RSV-associated medically attended lower respiratory infection (MALRI) in RSV Season 1</measure>
    <time_frame>Up to 150 days</time_frame>
    <description>Percentage of participants with RSV-associated medically attended lower respiratory infection (MALRI) in RSV Season 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with RSV-associated hospitalization in RSV Season 1</measure>
    <time_frame>Up to 150 days</time_frame>
    <description>Percentage of participants with RSV-associated hospitalization in RSV Season 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with solicited injection-site AEs in RSV Season 2</measure>
    <time_frame>From approximately 393 days up to 400 days</time_frame>
    <description>Percentage of participants with solicited injection-site AEs in RSV Season 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with solicited daily body temperature with fever in RSV Season 2</measure>
    <time_frame>From approximately 393 days up to 400 days</time_frame>
    <description>Percentage of participants with solicited daily body temperature with fever in RSV Season 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with solicited systemic AEs in RSV Season 2</measure>
    <time_frame>From approximately 393 days up to 400 days</time_frame>
    <description>Percentage of participants with solicited systemic AEs in RSV Season 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with anaphylaxis/hypersensitivity AESI in RSV Season 2</measure>
    <time_frame>From approximately 393 days up to 440 days</time_frame>
    <description>Percentage of participants with anaphylaxis/hypersensitivity AESI in RSV Season 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with rash AESI in RSV Season 2</measure>
    <time_frame>From approximately 393 days up to 440 days</time_frame>
    <description>Percentage of participants with rash AESI in RSV Season 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with non-serious AEs in RSV Season 2</measure>
    <time_frame>From approximately 393 days up to 440 days</time_frame>
    <description>Percentage of participants with non-serious AEs in RSV Season 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with SAEs in RSV Season 2</measure>
    <time_frame>From approximately 393 days up to 575 days</time_frame>
    <description>Percentage of participants with SAEs in RSV Season 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of MK-1654 in RSV Season 1</measure>
    <time_frame>Up to 240 days</time_frame>
    <description>Serum concentration of MK-1654 after dose of MK-1654 in RSV Season 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of MK-1654 in RSV Season 2</measure>
    <time_frame>From approximately 393 days up to 550 days</time_frame>
    <description>Serum concentration of MK-1654 after dose of MK-1654 in RSV Season 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>RSV Infection</condition>
  <arm_group>
    <arm_group_label>MK-1654</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an intramuscular (IM) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palivizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive an IM injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-1654</intervention_name>
    <description>IM injection</description>
    <arm_group_label>MK-1654</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Palivizumab</intervention_name>
    <description>IM injection</description>
    <arm_group_label>Palivizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants at increased risk for severe RSV infection recommended to receive&#xD;
             palivizumab in accordance with national or local guidelines or professional society&#xD;
             recommendations.&#xD;
&#xD;
          -  Is available to complete the follow-up period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requires mechanical ventilation at time of enrollment.&#xD;
&#xD;
          -  Has a life expectancy &lt;6 months.&#xD;
&#xD;
          -  Has known hepatic or renal dysfunction, or chronic seizure disorder.&#xD;
&#xD;
          -  Is hospitalized at the time of randomization unless discharge is expected within 7&#xD;
             days after randomization.&#xD;
&#xD;
          -  Has severe immunodeficiency or is severely immunocompromised.&#xD;
&#xD;
          -  Has known hypersensitivity to any component of MK-1654 or palivizumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palivizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

